References:
Ruboxistaurin: LY 333531. Drug R. D. 2007, 8(3), 193-199. [online]
LY-333531 mesylate hydrate. Drugs Fut. 2000, 25(10), 1017. [online]
GL Engel et al. Salt form selection and characterization of LY333531 mesylate monohydrate. Int. J. Pharmaceutics 2000, 198(2), 239-247. [online]
MR Jirousek et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacy clohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J. Med. Chem. 1996, 39, 2664. [online]
Y Wu et al. Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats. J. Pharmacol. Sci. 2006, 101(4), 335-343. [online]
S Tang et al. Protein kinase C isozymes and their selectivity towards ruboxistaurin. Proteins. 2008, 72(1), 447-60. [online]
Chemical Name: 9H,18H-5,21:12,17-Dimethenodibenzo[e,k]pyrrolo[3.4-h][1,4,13]oxadiazacyclohexadecine-18,20(19H)-dione, 9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-, (9S)-, methanesulfonate (1:1)
